Conclusion of non-exclusive discount agreements in accordance with Section 130a, Paragraph 8 of Book V of the Social Code on drugs with the active ingredient Interferon beta 1b (L03AB08) within the period from June 1st, 2021 to May 31st, 2023 with the possibility of concluding a contract at any time (open-house model)

The AOK Rheinland-Pfalz / Saarland - Die Gesundheitskasse offers all interested pharmaceutical companies without a selection decision discount agreements with the active ingredient Interferon beta 1 b (L03AB08). Contracts are concluded as part of an "open house model". The contracts offered are not exclusive; Contracts with all market participants (pharmaceutical companies) are requested by the AOK Rheinland-Pfalz / Saarland - Die Gesundheitskasse. In the open house model, uniform conditions apply to all participants. The content of the contract, terms and conditions and access procedures are uniform - individual negotiations are not conducted.

The contract periods are a maximum of 24 months, the earliest contract start is 1.6.2021. All contracts end at the latest 24 months after the date of the earliest start of the contract, regardless of the date on which the respective contract was concluded. Joining or entering into a contract can take place within the 24-month period on the first of each month.

There is a right of termination six weeks at the end of each month in accordance with the provisions of the contract. Further information on the termination options can be found in the contract documents.

The AOK Rheinland-Pfalz / Saarland - Die Gesundheitskasse reserves the right to replace the non-exclusive open house discount agreements with exclusive discount agreements within the framework of Europe-wide tendering procedures during the contract period. With the entry into force of advertised, exclusive discount contracts, the open house contracts are terminated in accordance with the contractual regulation, ie the open house contracts end automatically.

Interested pharmaceutical companies can request the participation documents and the contract documents from the contact address given under I.1). Contracts for the active ingredient Interferon beta 1b (L03AB08) will be concluded for the first time with effect from June 1, 2021. Interested parties who would like to become a contractual partner on this date must submit the contract documents to the AOK Rheinland-Pfalz / Saarland - Die Gesundheitskasse by April 30, 2021. It depends on the access at the AOK Rheinland-Pfalz / Saarland - Die Gesundheitskasse.

Note: The first award in this procedure will be awarded at the earliest 10 calendar days after this EU notice has been published in the Official Journal. Later contracts are possible during the 24-month maximum term on the first of each month. In the case of interested parties who would like to become a contractual partner on these subsequent dates, the receipt of the contract documents including Annex 1 must be submitted at the latest by the end of the month preceding the month before the desired start of the contract (e.g. receipt on April 30th when the contract starts on 1.6.). The exact deadlines for receipt will be announced with the contract documents. The present publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or the procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation "open procedure", are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to regulations under public procurement law, unless they are mandatory for legal reasons, is not associated with this.